Histologic variability in solitary fibrous tumors reflects angiogenic and growth factor signaling pathway alterations

Human Pathology

Volumn 46, Issue 7, 2015, Pages 1015-1026

  Demicco, Elizabeth G ^a   Wani, Khalida ^b   Fox, Patricia S ^b   Bassett, Roland L ^b   Young, Eric D ^b   Lev, Dina ^b,c   Aldape, Kenneth D ^b   Lazar, Alexander J ^b   Wang, Wei Lien ^b  

^a MOUNT SINAI HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Angiogenesis; Growth factor; Hemangiopericytoma; Oncogenesis; Solitary fibrous tumor; Targeted therapy

Indexed keywords

ANGIOGENIC FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GROWTH FACTOR; INITIATION FACTOR 4E BINDING PROTEIN 1; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR A; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR B; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN KINASE B; PROTEIN S6; SCATTER FACTOR RECEPTOR; SOMATOMEDIN B; SOMATOMEDIN RECEPTOR; STEM CELL FACTOR; VASCULOTROPIN; ANGIOGENIC PROTEIN; SIGNAL PEPTIDE; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUTATIONAL ANALYSIS; PRIMARY TUMOR; PROGNOSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SOLITARY FIBROUS TUMOR; TISSUE MICROARRAY; TUMOR LOCALIZATION; CELL PROLIFERATION; CHEMISTRY; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; MUTATION; NEOVASCULARIZATION (PATHOLOGY); NUCLEOTIDE SEQUENCE; PATHOLOGY; PHENOTYPE; TUMOR VOLUME; VASCULARIZATION; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANGIOGENIC PROTEINS; BIOMARKERS, TUMOR; CELL PROLIFERATION; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; MUTATION; NEOVASCULARIZATION, PATHOLOGIC; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; SIGNAL TRANSDUCTION; SOLITARY FIBROUS TUMORS; TISSUE ARRAY ANALYSIS; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84931006684     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2015.03.014     Document Type: Article

References (35)

1. L. Guillou, J.A. Fletcher, C.D.M. Fletcher, and N. Mandahl Extrapleural solitary fibrous tumor and haemangiopericytoma C.D.M. Fletcher, K.K. Unni, F. Mertens, World Health Organization Classification of Tumours Pathology and Genetics of Tumours of Soft Tissue and Bone 2002 IARC Press Lyon 86 90
2. I.M. Cranshaw, P.D. Gikas, C. Fisher, K. Thway, J.M. Thomas, and A.J. Hayes Clinical outcomes of extra-thoracic solitary fibrous tumours Eur J Surg Oncol 35 2009 994 998
3. E.G. Demicco, M.S. Park, and D.M. Araujo Solitary fibrous tumor: a clinicopathological study of 110 cases and proposed risk assessment model Mod Pathol 25 2012 1298 1306
4. Y. Yamada, K. Kohashi, and F. Fushimi Activation of the Akt-mTOR pathway and receptor tyrosine kinase in patients with solitary fibrous tumors Cancer 120 2014 864 876
5. L. Schirosi, S. Lantuejoul, and A. Cavazza Pleuro-pulmonary solitary fibrous tumors: a clinicopathologic, immunohistochemical, and molecular study of 88 cases confirming the prognostic value of de Perrot staging system and p53 expression, and evaluating the role of c-kit, BRAF, PDGFRs (alpha/beta), c-met, and EGFR Am J Surg Pathol 32 2008 1627 1642
6. S. Stacchiotti, T. Negri, and E. Palassini Sunitinib malate and figitumumab in solitary fibrous tumor: patterns and molecular bases of tumor response Mol Cancer Ther 9 2010 1286 1297
7. M. Hajdu, S. Singer, R.G. Maki, G.K. Schwartz, M.L. Keohan, and C.R. Antonescu IGF2 over-expression in solitary fibrous tumours is independent of anatomical location and is related to loss of imprinting J Pathol 221 2010 300 307
8. Y. Li, Q. Chang, and B.P. Rubin Insulin receptor activation in solitary fibrous tumours J Pathol 211 2007 550 554
9. K. Pavelic, T. Cabrijan, and R. Hrascan Molecular pathology of hemangiopericytomas accompanied by severe hypoglycemia: oncogenes, tumor-suppressor genes and the insulin-like growth factor family J Cancer Res Clin Oncol 124 1998 307 314
10. D.R. Robinson, Y.M. Wu, and S. Kalyana-Sundaram Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing Nat Genet 45 2013 180 185
11. L. Schweizer, C. Koelsche, and F. Sahm Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein Acta Neuropathol 125 2013 651 658
12. J. Chmielecki, A.M. Crago, and M. Rosenberg Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors Nat Genet 45 2013 131 132
13. S. Barthelmess, H. Geddert, and C. Boltze Solitary fibrous tumors/hemangiopericytomas with different variants of the NAB2-STAT6 gene fusion are characterized by specific histomorphology and distinct clinicopathological features Am J Pathol 184 2014 1209 1218
14. E.G. Demicco, R.G. Maki, D.C. Lev, and A.J. Lazar New therapeutic targets in soft tissue sarcoma Adv Anat Pathol 19 2012 170 180
15. O.H. Iwenofu, R.D. Lackman, A.P. Staddon, D.G. Goodwin, H.M. Haupt, and J.S. Brooks Phospho-S6 ribosomal protein: a potential new predictive sarcoma marker for targeted mTOR therapy Mod Pathol 21 2008 231 237
16. L. Cen, K.J. Arnoczky, and F.C. Hsieh Phosphorylation profiles of protein kinases in alveolar and embryonal rhabdomyosarcoma Mod Pathol 20 2007 936 946
17. C.Y. Zou, K.D. Smith, and Q.S. Zhu Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor Mol Cancer Ther 8 2009 1157 1168
18. I.W. Chang, J.W. Lin, and Y.T. Wu The status of MGMT protein expression is a prognostic factor for meningeal hemangiopericytoma: a clinicopathologic and immunohistochemical study of 12 cases at a single institution J Neurooncol 105 2011 563 572
19. M.S. Park, S.R. Patel, and J.A. Ludwig Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor Cancer 117 2011 4939 4947
20. K.B. Peters, R. McLendon, M.A. Morse, and J.J. Vredenburgh Treatment of recurrent intracranial hemangiopericytoma with SRC-related tyrosine kinase targeted therapy: a case report Case Rep Oncol 3 2010 93 97
21. R. Quek, Q. Wang, and J.A. Morgan Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors Clin Cancer Res 17 2011 871 879
22. T. De Pas, F. Toffalorio, and P. Colombo Brief report: activity of imatinib in a patient with platelet-derived-growth-factor receptor positive malignant solitary fibrous tumor of the pleura J Thorac Oncol 3 2008 938 941
23. M. Prunotto, M. Bosco, and L. Daniele Imatinib inhibits in vitro proliferation of cells derived from a pleural solitary fibrous tumor expressing platelet-derived growth factor receptor-beta Lung Cancer 64 2009 244 246
24. J. Domont, C. Massard, N. Lassau, J.P. Armand, A. Le Cesne, and J.C. Soria Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed malignant haemangioperyctoma/solitary fibrous tumour Invest New Drugs 28 2010 199 202
25. M. von Mehren, C. Rankin, and J.R. Goldblum Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas Cancer 118 2012 770 776
26. R.G. Maki, D.R. D'Adamo, and M.L. Keohan Phase II study of sorafenib in patients with metastatic or recurrent sarcomas J Clin Oncol 27 2009 3133 3140
27. M. Delgado, E. Perez-Ruiz, J. Alcalde, D. Perez, R. Villatoro, and A. Rueda Anti-angiogenic treatment (sunitinib) for disseminated malignant haemangiopericytoma: a case study and review of the literature Case Rep Oncol 4 2011 55 59
28. S. George, P. Merriam, and R.G. Maki Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas J Clin Oncol 27 2009 3154 3160
29. S. Stacchiotti, T. Negri, and M. Libertini Sunitinib malate in solitary fibrous tumor (SFT) Ann Oncol 23 2012 3171 3179
30. K. Mulamalla, A.M. Truskinovsky, and A.Z. Dudek Rare case of hemangiopericytoma responds to sunitinib Transl Res 151 2008 129 133
31. Y.H. Tan, S. Krishnaswamy, and S. Nandi CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases PLoS One 5 2010 e8972
32. J.W. Tyner, L.B. Fletcher, and E.Q. Wang MET receptor sequence variants R970C and T992I lack transforming capacity Cancer Res 70 2010 6233 6237
33. J. Voortman, T. Harada, and R.P. Chang Detection and therapeutic implications of c-Met mutations in small cell lung cancer and neuroendocrine tumors Curr Pharm Des 19 2012 833 840
34. D.W. Neklason, M.W. Done, and N.R. Sargent Activating mutation in MET oncogene in familial colorectal cancer BMC Cancer 11 2011 424
35. J.R. Graff, and S.G. Zimmer Translational control and metastatic progression: enhanced activity of the mRNA cap-binding protein eIF-4E selectively enhances translation of metastasis-related mRNAs Clin Exp Metastasis 20 2003 265 273